Background: Primary non-Hodgkin’s lymphoma involving the uterine cervix is extremely rare with a frequency of 0.008% of all cervical tumors. No standard treatment has been defined for this disease. Case: A 29-year-old Caucasian woman with primary non-Hodgkin stage IE lymphoma of the uterine cervix was treated with neoadjuvant chemotherapy and conservative surgery. Three years after completion of primary treatment, she became pregnant and successfully delivered a full-term healthy baby. Conclusion: This case report supports the data that a conservative strategy consisting of neoadjuvant chemotherapy followed by a uterine-preserving approach represents an adequate option for young highly motivated patients who desire to preserve the childbearing potential.
ObjectiveTo investigate the effect of treatment with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS), versus primary debulking surgery (PDS), on quality of life (QoL) in patients with advanced epithelial ovarian cancer (EOC).DesignRandomised trial conducted in a single institution.SettingDivision of Gynaecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.SamplePatients with stage‐IIIC/IV EOC and high tumour load.MethodsPatients were randomised (1:1) to undergo either PDS (PDS group) or NACT followed by IDS (NACT/IDS group).Main outcome measuresQuality‐of‐life (QoL) data, assessed using the European Organization for Research and Treatment of Cancer core QoL questionnaire (QLQ‐C30) and ovarian cancer module (OV28); co‐primary outcomes were the QLQ‐C30 global health score at 12 months (cross‐sectional analysis) and the difference in mean QLQ‐C30 global health score over time between treatment groups (longitudinal analysis).ResultsFrom October 2011 to May 2016, 171 patients were enrolled (PDS = 84; NACT/IDS = 87). We observed no clinical or statistically significant difference between treatment groups in any of the QoL functioning scales at 12 months, including QLQ‐C30 global health score (NACT/IDS group vs PDS group, mean difference 4.7, 95% CI −4.99 to 14.4, p = 0.340). Over time, we found lower global health scores for those undergoing PDS than for those receiving NACT (difference in mean score 6.27, 95% CI 0.440–12.11, p = 0.035), albeit this was not clinically relevant.ConclusionsWe found no difference in global QoL related to treatment approach at 12 months, even though patients in the NACT/IDS group reported better global health scores across the 12‐month period compared with the PDS group; these findings further confirm that NACT/IDS might be a feasible option for patients unsuitable for PDS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.